Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
Top Page
Nautilus Biotechnolgy
(NASDAQ:NAUT)
Rating:41Neutral
Price Target:―
Positive Factors
Cost Management
Cost management and a 16% reduction in force should enable the cash runway to extend to 2027.
Financial Performance
Ongoing cash management efforts are encouraging, as well as the progress towards a differentiated proteomics offering.
Negative Factors
Commercial Launch Delay
NAUT traded down nearly (20%) after another commercial launch timeline delay, this one a push out to late 2026.
Internal Milestones
The company was behind on internal milestones with respect to a major broadscale goal of quantifying a significant number of proteins from a complex sample.
Nautilus Biotechnolgy (NAUT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$92.09M
Dividend YieldN/A
Average Volume (3M)424.53K
Price to Earnings (P/E)―
Beta (1Y)1.99
Revenue GrowthN/A
EPS Growth-1.20%
CountryUS
Employees134
SectorHealthcare
Sector Strength44
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding126,148,470
10 Day Avg. Volume954,427
30 Day Avg. Volume424,533
Financial Highlights & Ratios
PEG Ratio78.02
Price to Book (P/B)4.16
Price to Sales (P/S)0.00
P/FCF Ratio-7.09
Enterprise Value/Market Cap3.79
Enterprise Value/Revenue21.28
Enterprise Value/Gross Profit-108.89
Enterprise Value/Ebitda-1.17
Forecast
1Y Price Target
$2.75Price Target Upside276.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Nautilus Biotechnolgy Business Overview & Revenue Model
Company DescriptionNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
How the Company Makes MoneyNautilus Biotechnology generates revenue primarily through the commercialization of its proteomics platform. The company offers its technology to pharmaceutical companies, academic institutions, and research organizations, which use it to conduct detailed protein analysis. Key revenue streams include the sale of instruments, consumables, and related services required to operate the platform. Additionally, Nautilus may engage in strategic partnerships and collaborations with other entities in the biotech and pharmaceutical industries, which can provide further revenue through joint research projects, licensing agreements, and milestone payments based on the successful achievement of specific research or development goals.
Nautilus Biotechnolgy Earnings Call Summary
Earnings Call Date:Apr 29, 2025
(Q1-2025)
| % Change Since: 7.35%|
Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment Positive
The earnings call reflected a generally positive outlook. Nautilus Biotechnology reported significant advancements in their tau proteoform assay, cost efficiency leading to reduced expenses, and a strong cash position. There is enthusiastic interest from the research community and promising early results in Alzheimer’s research. However, the company did face some challenges, including a reduction in workforce and slower progress in forming pharmaceutical partnerships. Overall, the positive aspects, particularly in technological advancements and financial health, outweigh the lowlights.Q1-2025 Updates
Positive Updates
Successful Tau Proteoform Assay Validation
The assay's reproducibility, accuracy, dynamic range, and sample compatibility aligned with launch specifications. Median percent error was approximately 10%, exceeding the target by a factor of three, and the median coefficient of variation was more than 15 times better than the target.
Cost Efficiency and Expense Reduction
Total operating expenses for Q1 2025 were $18.8 million, a 13% decrease compared to $21.6 million in Q1 2024. The reduction in expenses is due to cost efficiency and absence of nonrecurring costs from 2024.
Strong Cash Position
Nautilus ended the quarter with approximately $193 million in cash, cash equivalents, and investments, with a projected cash runway through 2027.
Positive Customer Feedback and Interest
Significant interest from proteomics researchers and potential partners in both targeted proteome and broad-scale discovery capabilities of Nautilus's platform.
Promising Alzheimer’s Disease Research
Early studies using the tau proteoform assay showed new insights into complex phosphorylation patterns in Alzheimer’s disease.
Negative Updates
Headcount Reduction
A 16% reduction in headcount across all areas of the business, indicating efforts to streamline operations and extend the cash runway.
Slower Pharma Partner Engagement
Engagements with pharmaceutical partners are progressing slowly due to external market turmoil and the novelty of the technology.
Company Guidance
During the Nautilus Biotechnology, Inc. First Quarter 2025 Earnings Conference Call, the company provided guidance highlighting significant advancements in their proteomic platform development. The focus was on targeted proteoform detection and broad scale discovery, with the tau proteoform assay showing promising results in reproducibility, accuracy (with a median percent error of approximately 10%), and dynamic range, exceeding expectations by a factor of three. They reported a 13% decrease in total operating expenses year-over-year, with research and development expenses at $11.5 million and a net loss of $16.6 million. The company anticipates launching their platform in late 2026 and projects their cash runway to extend through 2027, with $193 million in cash and equivalents at the end of Q1 2025. Nautilus is in discussions for potential partnerships, particularly in academic and nonprofit sectors, to further validate and demonstrate the platform's capabilities.Nautilus Biotechnolgy Financial Statement Overview
Summary
Nautilus Biotechnology is in an early growth phase with consistent zero revenue and significant net losses, typical for biotech startups. Strong cash reserves and low leverage offer some financial stability, but the ongoing operational losses and cash outflows pose significant risks.Income Statement
Nautilus Biotechnology has consistently reported zero revenue, reflecting its early-stage development status typical for biotech firms. The company faces significant net losses, with a negative net profit margin and no gross profit. Revenue growth is non-existent, while operating expenses remain high, adversely affecting EBIT and EBITDA margins.15
Very Negative
Balance Sheet
The balance sheet shows a relatively strong equity position with a consistent decrease in stockholders' equity over recent years, reflecting ongoing losses. The debt-to-equity ratio is favorable, indicating low leverage, but the negative equity in earlier years signals financial instability. The equity ratio is reasonably high, suggesting a good proportion of assets financed by equity.30
Negative
Cash Flow
The cash flow statement reveals negative free cash flow and operating cash flow, reflecting high cash burn typical for biotech startups. The free cash flow to net income ratio is negative, indicating cash outflows exceed inflows. However, substantial cash reserves provide a buffer against short-term financial challenges.20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.21M | 0.00 | -5.71M | -3.42M | -2.84M | -2.35M |
| EBITDA | -72.33M | -64.43M | -74.30M | -60.20M | -47.66M | -13.40M |
| Net Income | -68.66M | -70.78M | -63.67M | -57.92M | -50.31M | -15.62M |
Balance Sheet | ||||||
| Total Assets | 227.69M | 242.74M | 305.56M | 350.05M | 398.45M | 85.01M |
| Cash, Cash Equivalents and Short-Term Investments | 138.81M | 129.89M | 173.42M | 184.47M | 345.73M | 76.74M |
| Total Debt | 29.34M | 30.48M | 34.63M | 30.33M | 30.03M | 4.78M |
| Total Liabilities | 33.26M | 34.01M | 40.21M | 35.13M | 34.87M | 114.73M |
| Stockholders Equity | 194.44M | 208.73M | 265.35M | 314.92M | 363.58M | -29.72M |
Cash Flow | ||||||
| Free Cash Flow | -58.51M | -61.27M | -54.15M | -48.13M | -41.51M | -14.92M |
| Operating Cash Flow | -56.82M | -59.15M | -51.71M | -45.81M | -39.24M | -14.00M |
| Investing Cash Flow | 63.41M | 66.25M | -43.73M | -25.74M | -138.96M | -25.28M |
| Financing Cash Flow | 917.00K | 1.14M | 368.00K | 562.00K | 327.45M | 75.90M |
Nautilus Biotechnolgy Technical Analysis
Negative
0.73
Price Trends
0.74
Negative
0.94
Negative
1.64
Negative
Market Momentum
>-0.01
Negative
48.39
Neutral
20.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAUT, the sentiment is Negative. The current price of 0.73 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.74, and below the 200-day MA of 1.64, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.39 is Neutral, neither overbought nor oversold. The STOCH value of 20.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAUT.
Nautilus Biotechnolgy Risk Analysis
Nautilus Biotechnolgy disclosed 69 risk factors in its most recent earnings report. Nautilus Biotechnolgy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nautilus Biotechnolgy Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.55B | 0.39 | -61.90% | 2.32% | 17.14% | 1.55% | |
41 Neutral | $92.09M | ― | -30.93% | ― | ― | -1.20% | |
| $96.65M | ― | -20.53% | ― | ― | ― | ||
55 Neutral | $128.87M | ― | -24.73% | ― | -1.02% | -8.59% | |
39 Underperform | $106.13M | ― | -179.12% | ― | 30.23% | -21.32% | |
34 Underperform | $143.86M | ― | -44.50% | ― | ― | 52.54% | |
33 Underperform | $128.80M | ― | -79.05% | ― | ― | -0.42% |
* Healthcare Sector Average
Performance Comparison
NAUT
Nautilus Biotechnolgy
0.78
-1.49
-65.64%
XBIT
XBiotech
3.17
-2.62
-45.25%
OBIO
Orchestra BioMed Holdings
2.88
-4.69
-61.96%
SEER
Seer
2.21
0.57
34.76%
TIL
Instil Bio
23.81
13.59
132.97%
NMRA
Neumora Therapeutics, Inc.
0.78
-8.98
-92.01%
Nautilus Biotechnolgy Corporate Events
Executive/Board ChangesBusiness Operations and StrategyFinancial Disclosures
Nautilus Biotechnology Announces Board Changes for 2025
Negative
Feb 27, 2025
Nautilus Biotechnology announced changes in its board of directors for the 2025 annual meeting, with Vijay Pande and Michael Altman stepping down, and Matthew McIlwain transitioning to a Class I director to maintain board balance. The company also reported its financial results for the fourth quarter and fiscal year 2024, highlighting a slight increase in operating expenses and a net loss compared to the previous year. Nautilus plans to launch its proteome analysis platform in late 2026 and has reduced its workforce by 16% to align resources with development goals, aiming to extend its cash runway through 2027.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.